Telix Pharmaceuticals: Strong Financial Performance and Growth Potential Drive Buy Rating

Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Telix Pharmaceuticals, retaining the price target of A$35.00.

Tara Bancroft has given her Buy rating due to a combination of factors that highlight Telix Pharmaceuticals’ strong financial performance and potential for future growth. The company reported a significant revenue increase in the second quarter, with total revenue reaching $204 million, marking a 10% rise quarter-over-quarter and a 63% increase year-over-year. This growth was primarily driven by Illuccix, which exceeded expectations with a 12% sales beat, contributing to a 6% overall revenue beat for the first half of the year.
Additionally, Telix has maintained its 2025 revenue guidance, suggesting confidence in its growth trajectory despite potential challenges. The anticipated updates in their pipeline, particularly the Phase III TLX591 data, are expected to further bolster investor confidence. Moreover, the recent launch of Gozellix and its new permanent HCPCS code are promising developments that could help mitigate any negative impacts from changes in reimbursement policies. These factors collectively underpin Bancroft’s positive outlook and Buy rating for Telix Pharmaceuticals.

In another report released on July 18, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a A$27.00 price target.